Arthroscopic management of unexplained pain following total knee arthroplasty

Introduction Arthrofibrosis develops in 3–10% of knees after total knee arthroplasty (TKA), which may result in pain and restricted range-of-motion. Treatment options include manipulation under anaesthesia, arthroscopic debridement, and quadricepsplasty, but there is little consensus on their effica...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Archives of orthopaedic and trauma surgery 2022-06, Vol.142 (6), p.1109-1115
Hauptverfasser: Butnaru, Michaël, Senioris, Antoine, Pagenstert, Geert, Müller, Jacobus H., Saffarini, Mo, Dujardin, Franck, Courage, Olivier
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Introduction Arthrofibrosis develops in 3–10% of knees after total knee arthroplasty (TKA), which may result in pain and restricted range-of-motion. Treatment options include manipulation under anaesthesia, arthroscopic debridement, and quadricepsplasty, but there is little consensus on their efficacy for treatment of unexplained pain after TKA. The purpose of this study was to report the prevalence and characteristics of unexplained pain after TKA as revealed by arthroscopic exploration, and assess the efficacy of arthroscopic procedures to relieve pain. Materials and methods From a consecutive series of 684 TKAs, 11 patients (1.6%) had unexplained pain at 7–48 months after TKA. Causes of pain remained unidentified after systematic and differential assessment, but arthroscopic exploration revealed fibrotic tissues, which were debrided during the same procedure. Patients were assessed first at 6–61 months and last at 90–148 months, with pain on a visual analog scale (pVAS) and range-of-motion recorded during both assessments, but Oxford Knee Score (OKS) and Forgotten Joint Score (FJS) only during the last assessment. Residual pain was classified as little or no pain (pVAS, 0–1), moderate pain (pVAS, 2–4), and severe pain (pVAS, 5–10). Results At first follow-up ( n  = 11) pVAS improved by 4.1 ± 1.1 ( p  
ISSN:1434-3916
0936-8051
1434-3916
DOI:10.1007/s00402-021-03924-x